Sun Pharmaceutical Industries Reports Q2 FY27 Financial Results

Sun Pharmaceutical Industries reported Q2 FY27 consolidated revenue of Rs 16,198.7 crore, up 11.9% year over year, supported by growth in India and emerging markets. Net profit fell 36.2% to Rs 1,989 crore, reflecting exceptional charges tied to its proposed Organon & Co. acquisition and a US antitrust litigation settlement. Adjusted net profit increased 1.4% to Rs 3,162 crore, while EBITDA rose 4.8% to Rs 4,743.9 crore.